Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. [electronic resource]
Producer: 20150914Description: 455-70 p. digitalISSN:- 1545-326X
- Benzamides -- therapeutic use
- Breast Neoplasms -- drug therapy
- Drug Resistance, Neoplasm
- Enzyme Inhibitors -- therapeutic use
- Female
- Genes, BRCA1
- Genes, BRCA2
- Humans
- Mutation
- Neoplasms -- drug therapy
- Neoplasms, Cystic, Mucinous, and Serous -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- therapeutic use
- Piperazines -- therapeutic use
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.